To include your compound in the COVID-19 Resource Center, submit it here.

FDA reviewing Clovis' Rubraca for ovarian cancer maintenance

FDA accepted and granted Priority Review to an sNDA from Clovis Oncology

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE